Novo Nordisk Other Share Holders Equity 2010-2024 | NVO

Novo Nordisk other share holders equity from 2010 to 2024. Other share holders equity can be defined as field containing the sum of all current assets that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
  • Novo Nordisk other share holders equity for the quarter ending September 30, 2024 was $-0.235B, a 298.55% decline year-over-year.
  • Novo Nordisk other share holders equity for 2023 was $0.185B, a 46.57% decline from 2022.
  • Novo Nordisk other share holders equity for 2022 was $0.347B, a 227.17% decline from 2021.
  • Novo Nordisk other share holders equity for 2021 was $-0.273B, a 95.39% increase from 2020.
Novo Nordisk Annual Other Share Holders Equity
(Millions of US $)
2023 $185
2022 $347
2021 $-273
2020 $-140
2019 $-104
2018 $-313
2017 $53
2016 $-200
2015 $-53
2014 $-268
2013 $161
2012 $188
2011 $-41
2010 $53
2009 $133
Novo Nordisk Quarterly Other Share Holders Equity
(Millions of US $)
2024-09-30 $-235
2024-06-30 $-11
2024-03-31 $-85
2023-12-31 $185
2023-09-30 $118
2023-06-30 $279
2023-03-31 $339
2022-12-31 $347
2022-09-30 $346
2022-06-30 $119
2022-03-31 $-78
2021-12-31 $-273
2021-09-30 $-358
2021-06-30 $-337
2021-03-31 $-367
2020-12-31 $-140
2020-09-30 $-116
2020-06-30 $-63
2020-03-31 $-136
2019-12-31 $-104
2019-09-30 $-185
2019-06-30 $-143
2019-03-31 $-265
2018-12-31 $-313
2018-09-30 $-308
2018-06-30 $-332
2018-03-31 $17
2017-12-31 $53
2017-09-30 $188
2017-06-30 $137
2017-03-31 $-134
2016-12-31 $-200
2016-09-30 $-35
2016-06-30 $-65
2016-03-31 $104
2015-12-31 $-53
2015-09-30 $-30
2015-06-30 $-112
2015-03-31 $-485
2014-12-31 $-268
2014-09-30 $-231
2014-06-30 $6
2014-03-31 $127
2013-12-31 $161
2013-09-30 $137
2013-06-30 $121
2013-03-31 $133
2012-12-31 $188
2012-09-30 $86
2012-06-30 $-9
2012-03-31 $91
2011-12-31 $-41
2011-09-30 $0
2011-06-30 $0
2011-03-31 $172
2010-12-31 $53
2010-09-30 $0
2010-06-30 $0
2010-03-31 $0
2009-12-31 $133
2009-09-30 $138
2009-06-30 $21
2009-03-31 $-167
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $481.063B $33.708B
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $789.394B 81.76
Johnson & Johnson (JNJ) United States $374.313B 15.18
AbbVie (ABBV) United States $352.544B 18.56
Merck (MRK) United States $260.350B 17.30
Novartis AG (NVS) Switzerland $217.584B 14.46
AstraZeneca (AZN) United Kingdom $199.957B 17.81
Pfizer (PFE) United States $151.422B 10.36
Sanofi (SNY) $130.241B 11.80
Innoviva (INVA) United States $1.263B 10.51